KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Show more

Location: 55 Cambridge Parkway, Cambridge, MA, 02142, United States | Website: https://www.kalvista.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

624.9M

52 Wk Range

$7.30 - $16.32

Previous Close

$12.51

Open

$12.55

Volume

480,988

Day Range

$12.18 - $12.78

Enterprise Value

516.5M

Cash

220.6M

Avg Qtr Burn

-38.23M

Insider Ownership

1.65%

Institutional Own.

Qtr Updated

04/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EKTERLY® (sebetralstat) Details Hereditary angioedema	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sebetralstat (KVD900) (film coated) Details Hereditary angioedema	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD824 (plasma kallikrein enzyme inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD001 (IVT) Details Diabetic macular edema, Frontotemporal dementia with C9orf72 mutation, Dementia, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.